Amgen Inc. $AMGN Shares Purchased by Livforsakringsbolaget Skandia Omsesidigt

Livforsakringsbolaget Skandia Omsesidigt grew its position in shares of Amgen Inc. (NASDAQ:AMGN) by 19.6% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 56,218 shares of the medical research company’s stock after purchasing an additional 9,200 shares during the quarter. Amgen accounts for 0.7% of Livforsakringsbolaget Skandia Omsesidigt’s portfolio, making the stock its 28th largest position. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Amgen were worth $15,689,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of AMGN. GAMMA Investing LLC increased its position in shares of Amgen by 43,573.5% in the first quarter. GAMMA Investing LLC now owns 3,661,589 shares of the medical research company’s stock worth $1,140,768,000 after acquiring an additional 3,653,205 shares in the last quarter. Nuveen LLC bought a new position in Amgen during the first quarter valued at approximately $688,868,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Amgen in the 4th quarter valued at $193,339,000. Federated Hermes Inc. lifted its position in shares of Amgen by 48.5% in the first quarter. Federated Hermes Inc. now owns 2,037,169 shares of the medical research company’s stock worth $634,680,000 after buying an additional 665,555 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its position in Amgen by 128.9% during the first quarter. The Manufacturers Life Insurance Company now owns 1,065,694 shares of the medical research company’s stock worth $332,017,000 after purchasing an additional 600,096 shares during the period. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Stock Up 0.4%

Shares of AMGN opened at $275.83 on Friday. The firm has a market capitalization of $148.50 billion, a price-to-earnings ratio of 22.55, a PEG ratio of 2.39 and a beta of 0.49. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $339.17. The company has a debt-to-equity ratio of 7.24, a quick ratio of 0.98 and a current ratio of 1.31. The business’s fifty day moving average price is $290.76 and its two-hundred day moving average price is $290.85.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, August 5th. The medical research company reported $6.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.28 by $0.74. The business had revenue of $9.18 billion for the quarter, compared to analyst estimates of $8.86 billion. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The firm’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $4.97 earnings per share. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. On average, analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, September 12th. Shareholders of record on Friday, August 22nd were issued a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a yield of 3.5%. The ex-dividend date of this dividend was Friday, August 22nd. Amgen’s payout ratio is currently 77.84%.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. Piper Sandler raised their target price on Amgen from $328.00 to $342.00 and gave the company an “overweight” rating in a report on Monday, August 25th. Raymond James Financial assumed coverage on shares of Amgen in a research note on Wednesday, September 3rd. They issued a “market perform” rating for the company. UBS Group lowered their price target on Amgen from $326.00 to $317.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 6th. Citigroup upped their price target on Amgen from $305.00 to $310.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Finally, Morgan Stanley lifted their price objective on Amgen from $330.00 to $333.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 6th. Seven analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $304.43.

Insiders Place Their Bets

In related news, SVP Nancy A. Grygiel sold 1,267 shares of Amgen stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total transaction of $376,286.33. Following the transaction, the senior vice president owned 7,209 shares of the company’s stock, valued at $2,141,000.91. This trade represents a 14.95% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.76% of the company’s stock.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.